Dublin, Ireland

Francesco Manoni

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Trinity College Dublin. Active years: 2015.


 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Francesco Manoni: Innovator in Enantioselective Organic Reactions

Introduction

Francesco Manoni is a notable inventor based in Dublin, Ireland. He has made significant contributions to the field of organic chemistry, particularly in the area of enantioselective reactions. His work is essential for the development of new synthetic methods that have potential applications in medicinal chemistry.

Latest Patents

Francesco holds a patent for "Enantioselective organic anhydride reactions." This patent discloses a synthetic method that involves reacting an enolisable C-C organic anhydride with a second compound, which can be an aldehyde, a ketone, an aldimine, a ketimine, or a Michael Acceptor. The process utilizes a bifunctional organocatalyst and is particularly useful for the enantioselective synthesis of medicinally relevant heterocycles, such as dihydroisocoumarins and dihydroisoquinolinones. He has 1 patent to his name.

Career Highlights

Francesco is affiliated with Trinity College Dublin, where he conducts his research and development work. His academic background and research focus have positioned him as a key figure in the field of organic synthesis.

Collaborations

Francesco has collaborated with notable colleagues, including Sean Tallon and Stephen Joseph Connon. These collaborations have further enriched his research and contributed to advancements in organic chemistry.

Conclusion

Francesco Manoni is a distinguished inventor whose work in enantioselective organic reactions has the potential to impact medicinal chemistry significantly. His contributions to the field are noteworthy, and his ongoing research continues to inspire innovation.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…